CU23679A1 - Variantes de pertactinas para uso vacunal - Google Patents

Variantes de pertactinas para uso vacunal

Info

Publication number
CU23679A1
CU23679A1 CU20070240A CU20070240A CU23679A1 CU 23679 A1 CU23679 A1 CU 23679A1 CU 20070240 A CU20070240 A CU 20070240A CU 20070240 A CU20070240 A CU 20070240A CU 23679 A1 CU23679 A1 CU 23679A1
Authority
CU
Cuba
Prior art keywords
engineering
vaccines
pertactin
pertactines
vaccine
Prior art date
Application number
CU20070240A
Other languages
English (en)
Inventor
Leal Yoelys Cruz
Medina Tamara Menendez
Acosta Anabel Alvarez
Vazquez Diogenes Quintana
Nieto Gerardo Enrique Guillen
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20070240A priority Critical patent/CU23679A1/es
Priority to US12/739,658 priority patent/US8569470B2/en
Priority to PCT/CU2008/000009 priority patent/WO2009056076A1/es
Priority to KR1020107011928A priority patent/KR20100093548A/ko
Priority to CA2702697A priority patent/CA2702697A1/en
Priority to EP08845509A priority patent/EP2216045A1/en
Priority to MX2010004706A priority patent/MX2010004706A/es
Priority to CN2008801141194A priority patent/CN101878038B/zh
Priority to BRPI0817898 priority patent/BRPI0817898A2/pt
Priority to RU2010121646/10A priority patent/RU2499046C2/ru
Priority to ARP080104709A priority patent/AR069086A1/es
Publication of CU23679A1 publication Critical patent/CU23679A1/es
Priority to US13/966,948 priority patent/US20140011216A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se enmarca en el campo de la biomedicina, y comprende la ingenierización de la proteína pertactina (Prn) para su obtención y uso en vacunas bacterianas, más particularmente en vacunas acelulares contra Bordetella pertussis. Las pertactinas ingenierizadas abarcan en su estructura el polimorfismo de diferentes cepas, y al ensayarse como vacunas inducen una respuesta de anticuerpos de mayor capacidad protectora y de mayor actividad opsonofagocítica. Las variantes ingenierizadas de pertactina de esta invención son aplicables en la medicina humana y veterinaria.
CU20070240A 2007-10-30 2007-10-30 Variantes de pertactinas para uso vacunal CU23679A1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CU20070240A CU23679A1 (es) 2007-10-30 2007-10-30 Variantes de pertactinas para uso vacunal
EP08845509A EP2216045A1 (en) 2007-10-30 2008-10-17 Engineered pertactin variants for vaccine use
PCT/CU2008/000009 WO2009056076A1 (es) 2007-10-30 2008-10-17 Variantes ingenierizadas de pertactina para uso vacunal
KR1020107011928A KR20100093548A (ko) 2007-10-30 2008-10-17 백신 용도의 유전자 조작된 퍼탁틴 변이체
CA2702697A CA2702697A1 (en) 2007-10-30 2008-10-17 Engineered pertactin variants for vaccine use
US12/739,658 US8569470B2 (en) 2007-10-30 2008-10-17 Engineered pertactin variants for vaccine use
MX2010004706A MX2010004706A (es) 2007-10-30 2008-10-17 Variantes ingenierizadas de pertactina para uso vacunal.
CN2008801141194A CN101878038B (zh) 2007-10-30 2008-10-17 用于疫苗用途的经改造的百日咳杆菌粘附素变体
BRPI0817898 BRPI0817898A2 (pt) 2007-10-30 2008-10-17 Sequência polinucleotídica, composição farmacêutica, vacina, vetor de expressão em mamíferos, vacina, método para a deteccção de infecção por bordetella, e, kit diagnóstico para a detecção de presença ou ausência de anticorpos contra bordetella
RU2010121646/10A RU2499046C2 (ru) 2007-10-30 2008-10-17 Полинуклеотидная последовательность, кодирующая сконструированный белок пертактин, вектор, включающий такую последовательность, и вакцинные композиции, содержащие белок пертактина или вектор
ARP080104709A AR069086A1 (es) 2007-10-30 2008-10-28 Variantes ingenierizadas de pertactina para uso vacunal
US13/966,948 US20140011216A1 (en) 2007-10-30 2013-08-14 Engineered pertactin variants for vaccine use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20070240A CU23679A1 (es) 2007-10-30 2007-10-30 Variantes de pertactinas para uso vacunal

Publications (1)

Publication Number Publication Date
CU23679A1 true CU23679A1 (es) 2011-07-11

Family

ID=40473455

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20070240A CU23679A1 (es) 2007-10-30 2007-10-30 Variantes de pertactinas para uso vacunal

Country Status (11)

Country Link
US (2) US8569470B2 (es)
EP (1) EP2216045A1 (es)
KR (1) KR20100093548A (es)
CN (1) CN101878038B (es)
AR (1) AR069086A1 (es)
BR (1) BRPI0817898A2 (es)
CA (1) CA2702697A1 (es)
CU (1) CU23679A1 (es)
MX (1) MX2010004706A (es)
RU (1) RU2499046C2 (es)
WO (1) WO2009056076A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60133734T2 (de) 2000-05-25 2009-05-14 Institut Pasteur Polypeptide die polymorphismen aus bordertella pertussis, bordetella parapertussis und bordetella bronchiseptica pertactin wiederholende regionen enthalten, ihre verwendung in diagnostik und immunogene zusammensetzungen
EP1174505A1 (en) 2000-06-30 2002-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur (Poly)peptides for the preparation of vaccines against Bordetella pertussis and/or Bordetella parapertussis, vaccines based upon such (poly)peptides, and antibodies against such peptides
CA2539715C (en) * 2003-10-02 2015-02-24 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
UA40596U (ru) * 2006-05-16 2009-04-27 Институт Проблем Безопасности Атомных Электростанций Национальной Академии Наук Украины Энергоблок атомной электростанции

Also Published As

Publication number Publication date
BRPI0817898A2 (pt) 2015-05-05
US20140011216A1 (en) 2014-01-09
KR20100093548A (ko) 2010-08-25
MX2010004706A (es) 2010-05-27
CN101878038B (zh) 2013-11-06
RU2499046C2 (ru) 2013-11-20
CN101878038A (zh) 2010-11-03
RU2010121646A (ru) 2011-12-10
US20110070265A1 (en) 2011-03-24
EP2216045A1 (en) 2010-08-11
AR069086A1 (es) 2009-12-30
WO2009056076A1 (es) 2009-05-07
CA2702697A1 (en) 2009-05-07
US8569470B2 (en) 2013-10-29

Similar Documents

Publication Publication Date Title
BR112012020863A2 (pt) formas de rifaximina e usos das mesmas
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
BR112013004914A2 (pt) "composições de pele e métodos de uso das mesmas".
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
BRPI0919958A2 (pt) balão de cateter radiopaco deformável e resistente à ruptura e métodos para uso do mesmo em um procedimento cirúrgico intravascular
BRPI1013432A2 (pt) derivado de indolizina e uso do mesmo para propósitos médicos
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
ECSP077888A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
TR201821029T4 (tr) Geliştirilmiş antı-IL-23p19 antikorları.
AR075913A1 (es) Metodo para preparar un conjugado polipeptidico fisiologicamente activo de sitio especifico
BRPI0917478A8 (pt) uso de beta-lactamase bacteriana para diagnóstico in vitroe geração de imagem, diagnóstico e terapêutica in vivo
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
DOP2015000162A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos
CY1116186T1 (el) Μακροκυκλικες ενωσεις και μεθοδοι για την παραγωγη τους
WO2010053610A3 (en) Stable anthrax vaccine formulations
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
BR112012003760A2 (pt) Sistema de cultura de explante de pele humana e uso do mesmo
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas
BR112012018840A2 (pt) proteínas recombinantes para uso em vacina, anticorpos contra as ditas proteínas e métodos de diagnósticos e terapêuticos incluindo as mesmas
IT1398768B1 (it) Uso di microrna-199b-5p in campo medico e diagnostico.

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)